Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Given Average Rating of “Moderate Buy” by Brokerages

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $8.20.

WHWK has been the topic of several research analyst reports. Leerink Partners began coverage on Whitehawk Therapeutics in a research note on Monday, July 13th. They set an “outperform” rating and a $9.00 price target on the stock. B. Riley Financial started coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They set a “buy” rating and a $10.00 price objective for the company. Weiss Ratings downgraded Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, June 5th. Wall Street Zen raised Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Oppenheimer restated an “outperform” rating and issued a $7.00 price target on shares of Whitehawk Therapeutics in a research report on Friday, May 8th.

Institutional Trading of Whitehawk Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics in the fourth quarter valued at approximately $28,000. OMERS ADMINISTRATION Corp purchased a new stake in Whitehawk Therapeutics during the first quarter worth approximately $40,000. Dimensional Fund Advisors LP purchased a new stake in Whitehawk Therapeutics during the 3rd quarter worth $84,000. Deutsche Bank AG purchased a new stake in shares of Whitehawk Therapeutics during the 2nd quarter valued at about $145,000. Finally, Bank of America Corp DE purchased a new position in shares of Whitehawk Therapeutics in the second quarter valued at $159,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Stock Up 2.6%

NASDAQ:WHWK opened at $4.76 on Wednesday. The firm’s fifty day simple moving average is $4.16 and its 200-day simple moving average is $3.88. The stock has a market cap of $271.36 million, a PE ratio of -4.25 and a beta of 0.76. Whitehawk Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. Equities analysts anticipate that Whitehawk Therapeutics will post -1.1 earnings per share for the current year.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.